Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 7 of 7 publications.

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Chen ST, Katzka DA. Satisfaction with and adherence to off-label corticosteroids in adolescents and adults with eosinophilic esophagitis: results of a web-based survey in the United States. J Clin Gastroenterol. 2025 Feb;59(2):138-46. doi: 10.1097/MCG.0000000000002006

George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w

Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7

Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3

Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x

Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4

Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis c virus in a United States managed care population. J Clin Gastroenterol. 2011 Feb 1;45(2):e17-24.